Week Ending October 03, 2022

Transient Systemic Autophagy Inhibition is Selectively and Irreversibly Deleterious to Lung Cancer 
“Autophagy is a conserved catabolic process that maintains cellular homeostasis. Autophagy supports lung tumorigenesis and is a potential therapeutic target in lung cancer. A better understanding of the importance of tumor cell-autonomous versus systemic autophagy in lung cancer could facilitate clinical translation of autophagy inhibition.”

Selpercatinib Is Approved for 2 RET Fusion–Positive Solid Tumors, Non–Small Cell Lung Cancer
“Selpercatinib (Retevmo) was recently approved for 2 new solid tumor indications. The kinase inhibitor was granted regular approval for locally advanced or metastatic RET fusion–positive non–small cell lung cancer (NSCLC).1 It was also granted accelerated approval for patients with solid tumor harboring a RET gene fusion mutation.”

Study on Chronic Obstructive Pulmonary Disease and Lung Cancer: Web of Science-Based Bibliometric and Visual Analysis
“Chronic obstructive pulmonary disease (COPD) is one of the main risk factors for lung carcinomas. This study aimed to analyze and construct a model to assess scientific publications on the relationship between COPD and lung carcinomas.”

Self-Reported Lung-Related Comorbidities Have No Impact on LCS Outcomes
“Patients undergoing lung cancer screening (LCS) who self-reported lung-related comorbidities did not have differing outcomes compared with those not reporting conditions. These findings were published in JAMA Network Open.”

Policy, resources crucial for lung cancer screening: study
“A Veterans Health Administration project that provided resources for lung cancer screening programs increased the number of veterans screened, according to a study published in the September issue of the journal CHEST.”

Expensive Targeted Lung Cancer Therapies Need to Be Tailored to the Right Patient
“Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.”

What Are the Symptoms of Stage 1 Lung Cancer?
“You may not experience any symptoms if you have stage 1 lung cancer. However, people with symptoms may notice persistent coughing, a cough with blood, and shortness of breath.”

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

How to Select Treatment for Resectable Stage III Lung Cancer